Advertisement
U.S. Markets open in 4 hrs 23 mins
S&P Futures
5,968.25 +10.00 (+0.17%) Dow Futures
43,962.00 +61.00 (+0.14%) Nasdaq Futures
20,945.00 +51.00 (+0.24%) Russell 2000 Futures
2,410.80 +5.00 (+0.21%) Crude Oil
71.27 -0.42 (-0.59%) Gold
2,671.10 -5.20 (-0.19%)
Elevation Oncology, Inc. (ELEV)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 0.5600 |
| Open | 0.5900 |
| Bid | 0.5268 x 200 |
| Ask | 0.5723 x 200 |
| Day's Range | 0.5400 - 0.5900 |
| 52 Week Range | 0.3630 - 5.8300 |
| Volume | |
| Avg. Volume | 820,447 |
| Market Cap | 32.509M |
| Beta (5Y Monthly) | 1.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8000 |
| Earnings Date | Nov 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
PR NewswireElevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the third quarter ended September 30, 2024, and highlighted recent business achievements.
ZacksWhat Makes Elevation Oncology (ELEV) a New Strong Buy Stock
Elevation Oncology (ELEV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.